Completed PHASE2 INTERVENTIONAL 2-arm NCT01420744

Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP (CIGMA)

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group, Adaptive Group-sequential Phase II Study, to Determine the Efficacy and Safety of BT086 as an Adjunctive Treatment in Severe Community Acquired Pneumonia (sCAP)

Sponsor: Biotest

Conditions Community Acquired Pneumonia

Interventions 1% Human Albumin infusion BT086

Updated 6 times since 2017 Last updated: Jul 28, 2015 Started: Aug 31, 2011 Primary completion: Feb 28, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Community Acquired Pneumonia, this trial is completed. The trial is conducted by Biotest and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biotest

Data source: Biotest

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Badalona, Spain , Barcelona, Spain , Berlin, Germany , Brussels, Belgium , Cardiff, United Kingdom , Chemnitz, Germany , Cologne, Germany , Dresden, Germany , Erfurt, Germany , Frankfurt, Germany and 23 more locations